Toll‐like receptors and liver disease
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Toll‐like receptors (TLR s) are pattern recognition receptors that play an important role in host defence by recognizing pathogen‐associated molecular patterns (PAMP). Recent studies indicate that TLR signalling plays an important role in progression of chronic liver diseases. Ongoing clinical trials suggest that therapeutic manipulation of TLR pathways may offer novel means of reversing chronic liver diseases. Upon activation by their respective ligands, TLR s initiate an intracellular pro‐inflammatory/anti‐inflammatory signalling cascade via recruitment of various adaptor proteins. TLR associated signalling pathways are tightly regulated to keep a check on inappropriate production of pro‐inflammatory cytokines and interferons thereby preventing various autoimmune and inflammatory processes. Herein, we review the current state of knowledge of hepatic distribution, signalling pathways and therapeutic modulation of TLR s in chronic liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649 · cited 1×
“In experimental hepatic fibrosis models, reduced HSC activation and collagen deposition were also seen in TLR9 knockout mice (115).”
BackgroundPromotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Various animal models (122) and currently running phase III clinical trials (123) involving use of small molecule agents, such as Lipid A and TAK-42, a TLR-4 antagonist, have shown some benefit in management of septic patients.”
BackgroundBeutler, B. A. (2009) · Blood · doi:10.1182/blood-2008-07-019307 · Cited by 840
Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 2×
“Upon treatment with DEN, mice deficient in TLR4 and MyD88 had a significant decline in incidence, size and number of liver tumours (59, 77).”
BackgroundMethodRivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693
Antibiotics prevent liver injury in rats following long-term exposure to ethanol
Adachi, Y., Moore, L. E., Bradford, B. U., Gao, W., & Thurman, R. G. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90027-6 · Cited by 692 · cited 1×
“A significant reduction in liver injury was noted upon gut flora alteration by antibiotic (75) and probiotics (76).”
BackgroundHritz, I., Mandrekar, P., Velayudham, A., Catalano, D., Dolganiuc, A., Kodys, K., Kurt‐Jones, E., & Szabo, G. (2008) · Hepatology · doi:10.1002/hep.22470 · Cited by 415
Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors
Chuang, T.-H., & Ulevitch, R. J. (2004) · Nature Immunology · doi:10.1038/ni1066 · Cited by 374
The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon
Wang, C., Chen, T., Zhang, J., Yang, M., Li, N., Xu, X., & Cao, X. (2009) · Nature Immunology · doi:10.1038/ni.1742 · Cited by 317
Iwami, K.-I., Matsuguchi, T., Masuda, A., Kikuchi, T., Musikacharoen, T., & Yoshikai, Y. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6682 · Cited by 273 · cited 1×
“Triad domain-containing protein 3 (TRIAD3A) (19), Radio protective 105 (RP105) (20), soluble TLR2 (sTLR2) and sTLR4 (21), and Single Ig IL1 receptorrelated molecule (SIGGR) (22) regulate the TLR signalling at the receptor level.”
BackgroundLiu, S., Gallo, D. J., Green, A. M., Williams, D. L., Gong, X., Shapiro, R. A., Gambotto, A. A., Humphris, E. L., Vodovotz, Y., & Billiar, T. R. (2002) · Infection and Immunity · doi:10.1128/iai.70.7.3433-3442.2002 · Cited by 246
Machida, K., Tsukamoto, H., Mkrtchyan, H., Duan, L., Dynnyk, A., Liu, H. M., Asahina, K., Govindarajan, S., Ray, R., Ou, J.-H. J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807390106 · Cited by 223
Guo, J., Loke, J., Zheng, F., Hong, F., Yea, S., Fukata, M., Tarocchi, M., Abar, O. T., Huang, H., Sninsky, J. J., et al. (2009) · Hepatology · doi:10.1002/hep.22697 · Cited by 217
Altered Monocyte Responses to Defined TLR Ligands in Patients With Primary Biliary Cirrhosis *
Mao, T. K., Lian, Z.-X., Selmi, C., Ichiki, Y., Ashwood, P., Ansari, A. A., Coppel, R. L., Shimoda, S., Ishibashi, H., & Gershwin, E. M. (2005) · Hepatology · doi:10.1002/hep.20859 · Cited by 185 · cited 1×
“However, stimulation of TLRs 2, 3, 4, 5 and 9 on peripheral blood mononuclear cells (PBMC) significantly increased levels of pro-inflammatory cytokines production in those with PBC compared with healthy controls (105).”
BackgroundToll-like Receptor 4 and Hepatic Fibrogenesis
Pradere, J.-P., Troeger, J., Dapito, D., Mencin, A., & Schwabe, R. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255353 · Cited by 158
Shimoda, S., Harada, K., Niiro, H., Shirabe, K., Taketomi, A., Maehara, Y., Tsuneyama, K., Nakanuma, Y., Leung, P., Ansari, A. A., et al. (2011) · Hepatology · doi:10.1002/hep.24194 · Cited by 126 · cited 1×
“A potential role of TLR4 ligand-stimulated NK cells in destruction of BEC in the presence of TLR3 ligand-stimulated monocytes has been shown in PBC patients (102).”
BackgroundChuang, Y.-H., Lian, Z.-X., Tsuneyama, K., Chiang, B.-L., Ansari, A. A., Coppel, R. L., & Eric Gershwin, M. (2006) · Journal of Autoimmunity · doi:10.1016/j.jaut.2006.04.001 · Cited by 121 · cited 1×
“The biopsy findings in those with PBC show clustering of both autoreactive T cells and NK cells around small bile ducts (101).”
Background
Cited by
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Toll-like receptors activation, signaling, and targeting: an overview
El-Zayat, S. R., Sibaii, H., & Mannaa, F. A. (2019) · Bulletin of the National Research Centre · doi:10.1186/s42269-019-0227-2 · Cited by 556
Innate Immunity and Inflammation in NAFLD/NASH
Arrese, M., Cabrera, D., Kalergis, A. M., & Feldstein, A. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4049-x · Cited by 492
Eilam, Y., Khattib, H., Pintel, N., & Avni, D. (2023) · Global Challenges · doi:10.1002/gch2.202200177 · Cited by 101
Metadata
- Authors
- Kesar, V., & Odin, J. A.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2013-10-02
- Volume
- 34
- Issue
- 2
- Pages
- 184-196
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2075681199
- Cited by
- 104
- References
- 20
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.